A former NuVasive Inc. executive’s move to smaller spine-device competitor Alphatec Holdings Inc. has sparked a lawsuit, with Nuvasive claiming former president and COO Patrick Miles breached his contract and defrauded his former employer. Alphatec, however, said the allegations were false and decried the suit as a “PR stunt.”
NuVasive, Alphatec At Odds Over Exec Job Change
NuVasive has sued a former executive and board member for breach of contract after his move to competitor Alphatec. The smaller company says the basis of the lawsuit is “fictional.”
More from Legal & IP
• By
States and international regulatory bodies may increase their US enforcement role following federal staff cuts, Hyman Phelps & McNamara attorneys said in a recent webinar. The attorneys also expect False Claims Act enforcement and public health to remain key areas of focus at the federal level.
• By
A patient, Dena Lawler, is suing Boston Scientific and the US FDA over alleged harm from a spinal stimulator device. Lawler claims inadequate regulatory review allowed dangerous modifications to the device, which then caused her pain and other health issues. She is calling for reconsideration of the device approvals.
• By
Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.
• By
US President Trump has imposed sweeping tariffs that encompass medtech. These are expected to drive up costs, disrupt supply chains and hinder innovation, likely driving the EU to seek new trade partnerships to mitigate the impact.
More from Policy & Regulation
• By
The US Food and Drug Administration has announced new classifications for eight device types that reached market via the de novo process, with most of the newly classified products in the diagnostics sector.
• By
The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.
• By
States and international regulatory bodies may increase their US enforcement role following federal staff cuts, Hyman Phelps & McNamara attorneys said in a recent webinar. The attorneys also expect False Claims Act enforcement and public health to remain key areas of focus at the federal level.